Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05369078
Other study ID # THR-1442-C-607 (CHN)
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 1, 2021
Est. completion date May 31, 2022

Study information

Verified date December 2021
Source Newsoara Biopharma Co., Ltd.
Contact Owen Zhang
Phone 8621-52998027
Email owen.zhang@newsoara.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to investigate Safety, tolerability and pharmacokinetics in Chinese healthy subjects.


Description:

This was a single center, Phase 1, open-label SAD and MAD study designed to assess safety, tolerability and PK of orally administered THR-1442 tablets in Chinese healthy adults. Subjects were enrolled to receive 20mg THR-1442 tablet in Single dose group (20mg*1 day) and multiple dose group(20mg*7days). Blood samples for THR-1442 plasma concentrations were collected 0h till to 48hours.


Recruitment information / eligibility

Status Recruiting
Enrollment 16
Est. completion date May 31, 2022
Est. primary completion date May 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Be able to understand and be willing to sign informed consent and voluntarily participate in the study; 2. Chinese women or men aged 18-45 (including 18 and 45) at the time of screening; 3. Men or women who agree to effective contraception from the screening period until 30 days after the last dose in the trial; Agree to take at least one effective contraceptive measure; 4. During screening and baseline, male weight = 50.0kg, female weight = 45.0kg, body mass index (BMI) in the range of 19 ~ 25.0kg/m2 (including 19 and 25.0kg/m2), [BMI = weight (kg) / height 2 (M2)]; Exclusion Criteria: 1. According to the judgment of the site investigators, including clinical significant medical history in CNS, CV system, respiratory system, blood / hematopoietic system, gastrointestinal system, liver / kidney system,etc; 2. Subjects with specific allergic history or allergic constitution such as drugs, food and pollen, or allergic to SGLT2 inhibitors or similar drugs; 3. Alcoholics (drinking 14 units per week, each unit equivalent to 360mL beer or 150mL wine or 45mL alcohol of 40% alcohol), drug or drug dependence subjects; Smokers (smoking > 5 cigarettes per day or the same amount of other tobacco products); 4. Subjects with a history of bladder dysfunction, such as urinary incontinence, frequent urination or nocturia; 5. Blood donation within 3 months before screening, including component blood or massive blood loss (= 200ml), receiving blood transfusion or using blood products; 6. Subjects who used prescription drugs, traditional Chinese medicine, over-the-counter drugs (OTC), vitamins, dietary supplements or supplements (e.g. ginseng) within 4 weeks before the first administration; 7. From 7 days before the first dose to the whole study period, subjects who are unwilling or unable to guarantee to forbid by the following: no smoking, no alcohol, no caffeine containing products (including chocolate, tea, coffee, cola, etc.) and avoid strenuous exercise; 8. Those who are unwilling or unable to guarantee to forbid pitaya, grapefruit, mango, carambola, fruit juice and spicy food containing the above fruits from 7 days before taking the medicine and the whole test period; 9. The subject was unable to swallow the study drug or had gastrointestinal diseases leading to absorption disorders; 10. Subjects who had participated in any drug or medical device clinical trial within 3 months before screening;

Study Design


Intervention

Drug:
THR-1442 20mg Single dose
THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
THR-1442 20mg Multiple dose group
THR-1442 20mg is administrated QD for 7days, then follow till day 14.

Locations

Country Name City State
China Hangzhou First People's hospital Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Newsoara Biopharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Collect and evaluate TEAEs (including clinical AEs and Lab AEs) of THR-1442 in healthy subjects during study Collect data(TEAEs including clinical AEs and lab AEs) on Day7 and Day14 to evaluate THR1442 safety and tolerability Single dose:Baseline to day 7 ; Multiple dose:Baseline to Day14
Secondary Select and evaluate pharmacokinetic characteristics(AUC) of THR-1442 in healthy subjects during the study Collect blood samples on Single dose part and multiple dose part to evaluate THR1442 PK parameters (AUC) Single dose:Day1-Day7; Multiple dose:Day1- Day14
Secondary Select and evaluate pharmacokinetic characteristics(Cmax) of THR-1442 in healthy subjects during the study Collect blood samples on Single dose part and multiple dose part to evaluate THR1442 PK parameters (Cmax) Single dose:Day1-Day7; Multiple dose:Day1- Day14
See also
  Status Clinical Trial Phase
Completed NCT01373814 - Nutritional Therapy for Diabetic Cardiomyopathy
Recruiting NCT05469659 - Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) Phase 2
Completed NCT05376930 - Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM. Phase 3
Recruiting NCT04682795 - Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM N/A
Recruiting NCT06350890 - Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Phase 3
Completed NCT04634500 - The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes. Phase 3
Recruiting NCT03789695 - RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD Phase 4
Completed NCT04632862 - The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus. Phase 3
Completed NCT04688359 - Effectiveness of Nurse-coordinated Follow-up Program in Primary Care for People at Risk for T2DM N/A
Completed NCT05983289 - Single Escalating Dose Study Of HSK7653 In Healthy Subjects Phase 1
Recruiting NCT04272359 - Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
Completed NCT03467932 - A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus Phase 2
Completed NCT05376969 - Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin Phase 3
Recruiting NCT06415773 - Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Phase 3
Recruiting NCT06094491 - Virtual Diabetes Group Visits Across Health Systems Phase 2
Completed NCT05279911 - Effect of Low-level Laser Therapy on Type II Controlled Diabetic Patients After Dental Implant Insertion N/A
Active, not recruiting NCT03257449 - Effect of Viscous Soluble Fibres on Body Weight N/A
Terminated NCT04754334 - A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus Phase 3
Not yet recruiting NCT06293417 - To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
Not yet recruiting NCT03658031 - Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction Phase 3